Am J Transplant, Volume 21, Suppl 3 Archives - Page 34 of 139 - ATC Abstracts

2021 American Transplant Congress
Impact of Pre-Screening on OPTN Kidney Paired Donation Pilot Program Transplant and Refusal Rates
S. E. Booker¹, R. Leishman¹, J. Musick¹, M. Oley¹, T. Sandholm², J. Dickerson³, M. Pavlakis⁴, V. Casingal⁵
¹UNOS, Richmond, VA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of Maryland, College Park, MD, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Carolinas Medical Center, Charlotte, NC
*Purpose: The OPTN Kidney Paired Donation Pilot Program (KPDPP) donor pre-screen tool allows centers to review and pre-accept or pre-refuse potential donors for individual candidates…
2021 American Transplant Congress
Comparison of Allograft Outcomes in SLK Transplant Patients with and without ESLD: A UNOS Database Analysis
P. Kyriazis, H. Patel, P. Nissaisorakarn, F. Cardarelli, N. Agrawal
Transplant Division, Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Simultaneous liver and kidney transplants (SLKT) have started to gain ground in the treatment of liver disease with associated acute or chronic kidney disease.…
2021 American Transplant Congress
Highly Sensitized Simultaneous Liver-kidney Transplant Recipients Show a Reduction in Panel Reactive Antibodies and No Kidney Rejection 1-year Post-transplant
M. Moaddab, J. V. Nolte Fong, C. M. Mobley, A. Saharia, M. J. Hobeika, R. McMillan, S. G. Yi, R. J. Knight, A. Gaber, R. Ghobrial
Houston Methodist Hospital, Houston, TX
*Purpose: The liver is unique in that it is considered an immunologically tolerant organ against graft destruction by antibodies. Simultaneous liver-kidney transplantation (SLKT) are often…
2021 American Transplant Congress
Immunotherapy of Dc-cik Cells in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
S. Hsu, L. Jeng, H. Yang, A. Thorat
China Medical University Hospital, Taichung, Taiwan
*Purpose: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance in some…
2021 American Transplant Congress
Outcomes of Robotic Living Donor Right Hepatectomy in Liver Transplant Recipients: A Systematic Review and Meta-analysis
E. Lincango-Naranjo¹, E. Garces-Delgado², P. Solis-Pazmino³, H. Alexander-Leon⁴, G. Restrepo-Rodas², R. Mancero-Montalvo², C. J. Ponce², R. Cadena-Semanate², R. Vargas-Cordova⁵, G. Herrera-Cevallos⁶, A. Villarreal-Juris⁷, S. Vallejo¹, C. Liu-Sanchez⁸, L. P. Prokop⁹, A. D. Guerron¹⁰, O. J. Ponce¹, D. Moris¹¹
¹Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, ²Universidad Internacional del Ecuador, Quito, Ecuador, ³Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, ⁴Universidad de las Americas, Quito, Ecuador, ⁵Hospital General San Francisco IESS, Quito, Ecuador, ⁶Hospital Metropolitano, Quito, Ecuador, ⁷Universidad Central del Ecuador, Quito, Ecuador, ⁸Universidad Peruana Cayetano Heredia, Lima, Peru, ⁹Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ¹⁰Department of Surgery, Duke University, Durham, NC, ¹¹Department of surgery, Duke University, Durham, NC
*Purpose: Living donor adult-to-adult liver transplantation (LT) has emerged as a feasible alternative to deceased donors. Advances in hepatobiliary surgery have allowed the introduction of…
2021 American Transplant Congress
Outcomes of DCD Allografts in Liver Transplant Recipients with HCC
N. Gupta¹, J. Daum¹, B. Aqel², L. Mi³, J. Harbell⁴
¹School of Medicine, Mayo Clinic Arizona, Phoenix, AZ, ²Hepatology, Mayo Clinic Arizona, Phoenix, AZ, ³Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, ⁴Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ
*Purpose: Early studies demonstrated inferior survival for liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who received allografts from donation after cardiac death (DCD) donors…
2021 American Transplant Congress
Liver Transplantation with Super Obese Donors (BMI≥50) Grafts: An Acceptable Pathway to Expand the Donor Pool. Analysis of the OPTN/UNOS Liver Transplant Registry
P. Vargas¹, C. Argo², H. Zachary², M. Stotts², N. Intagliata², P. Northup², J. Oberholzer¹, S. Pelletier¹, N. Goldaracena¹
¹Transplant Surgery, University of Virginia Health System, Charlottesville, VA, ²Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, VA
*Purpose: We aimed to analyze the impact of donor body mass index (BMI) on recipient morbidity and survival following liver transplantation (LT).*Methods: The UNOS-STAR database…
2021 American Transplant Congress
A Pediatric Liver Allograft with an Occult Urea Cycle Defect Carrier Mutation Causing Delayed Graft Function and Metabolic Crisis After Liver Transplantation
A. Peters, M. Rezvani, C. Prada, K. Campbell
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: We report an interesting case of delayed graft function following pediatric liver transplantation, which was attributed to previously unrecognized urea cycle carrier genetic defect…
2021 American Transplant Congress
Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Data from the US Scientific Registry of Transplant Recipients (SRTR)
W. Fitzsimmons¹, J. Erdman², J. Wolfram³, D. Nimke², R. Croy², X. Wang², T. Weaver⁴, D. Schladt⁴
¹University of Illinois at Chicago, College of Pharmacy, Vernon Hills, IL, ²Astellas Pharma, Inc, Northbrook, IL, ³Astellas Pharma Europe BV, Leiden, Netherlands, ⁴Chronic Disease Research Group, Minneapolis, MN
*Purpose: There is currently no FDA approved immunosuppressive regimen for lung transplant (Tx) recipients; however, patients routinely receive a calcineurin inhibitor-based regimen. The SRTR database…
2021 American Transplant Congress
Use of Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients: A Scoping Review
A. G. Anderson, M. Eubank, K. Murray
University of Missouri, Columbia, MO
*Purpose: Immune checkpoint inhibitors (ICI) are an emerging treatment for numerous advanced diseases, but their safety and efficacy in immunosuppressed transplant patients is not known.…